HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/1/L199    most recent 00230.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Ammit, A. J. Articles by Roth, M. Search for Related Content PubMed PubMed Citation Articles by Ammit, A. J. Articles by Roth, M.

Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle

¹Respiratory Research Group, Faculty of Pharmacy, ²Department of Pharmacology, and ³Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia

Submitted 21 June 2006 ; accepted in final form 22 August 2006

Increased levels of IL-6 are documented in asthma, but its contribution to the pathology is unknown. Asthma is characterized by airway wall thickening due to increased extracellular matrix deposition, inflammation, angiogenesis, and airway smooth muscle (ASM) mass. IL-6 binds to a specific membrane-bound receptor, IL-6 receptor- (mIL-6R), and subsequently to the signaling protein gp130. Alternatively, IL-6 can bind to soluble IL-6 recpetor- (sIL-6R) to stimulate membrane receptor-deficient cells, a process called trans-signaling. We discovered that primary human ASM cells do not express mIL-6R and, therefore, investigated the effect of IL-6 trans-signaling on the pro-remodeling phenotype of ASM. ASM required sIL-6R to activate signal transducer and activator 3, with no differences observed between cells from asthmatic subjects compared with controls. Further analysis revealed that IL-6 alone or with sIL-6R did not induce release of matrix-stimulating factors (including connective tissue growth factor, fibronectin, or integrins) and had no effect on mast cell adhesion to ASM or ASM proliferation. However, in the presence of sIL-6R, IL-6 increased eotaxin and VEGF release and may thereby contribute to local inflammation and vessel expansion in airway walls of asthmatic subjects. As levels of sIL-6R are increased in asthma, this demonstration of IL-6 trans-signaling in ASM has relevance to the development of airway remodeling.

soluble interleukin-6 receptor-; gp130; signal transducer and activator 3; asthma; airway remodeling

This article has been cited by other articles:

				S. Zuyderduyn, M. B. Sukkar, A. Fust, S. Dhaliwal, and J. K. Burgess Treating asthma means treating airway smooth muscle cells Eur. Respir. J., August 1, 2008; 32(2): 265 - 274. [Abstract] [Full Text] [PDF]

				A. J Knox, K. Deacon, and R. Clifford Blanching the airways: steroid effects in asthma Thorax, April 1, 2007; 62(4): 283 - 285. [Full Text] [PDF]